FANCA Antibody [J21M8] | Primary Antibodies

Application: Reactivity: Human

Lane 1: 293T, Lane 2: HCT116, Lane 3: Hela, Lane 4: HT-29

Usage Information

Dilution
WB1:1000 IP1:100

Application
WB, IP

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
160 kDa

Datasheet & SDS

Biological Description

Specificity
FANCA Antibody [J21M8] detects endogenous levels of total FANCA protein.

Clone
J21M8

Synonym(s)
Fanconi anemia group A protein; FANCA

Background
FANCA serves as a core scaffold within the Fanconi anemia (FA) nuclear complex alongside FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, and FANCM, orchestrating interstrand crosslink repair and genome stability maintenance through coordinated protein interactions. FANCA organizes tetratricopeptide repeats and leucine zippers that facilitate assembly of the multi-subunit complex at chromatin lesions while binding Hsp90 chaperone for stability and nuclear trafficking. Upon DNA damage from crosslinkers like mitomycin C, the FA complex activates FANCL E3 ligase to mono-ubiquitinate FANCD2-FANCI heterodimer, recruiting downstream effectors FANCJ/BRIP1, FANCD1/BRCA2, and FANCN/PALB2 for fork remodeling, translesion synthesis, and homologous recombination via strand invasion coordinated with the BRCA1/53BP1 axis. FANCA directly catalyzes single-strand annealing of resected double-strand breaks independent of canonical FA pathway components, annealing complementary overhangs through bidirectional strand exchange that competes with RAD52 to favor error-free repair outcomes during replication stress. Hsp90 association stabilizes FANCA conformation against proteasomal degradation, with 17-AAG inhibition disrupting nuclear localization and impairing FANCD2 activation that sensitizes cells to crosslinking agents. FANCA shuttles to pericentriolar material and kinetochores to regulate the spindle assembly checkpoint via BUB1-BUBR1 phosphorylation networks, preventing anaphase onset until bipolar attachment while suppressing chromosome fragmentation through ultrafine bridge resolution. FANCA safeguards hematopoietic stem cell quiescence and self-renewal by integrating replication stress responses with mitotic fidelity in bone marrow niches.

Background

FANCA serves as a core scaffold within the Fanconi anemia (FA) nuclear complex alongside FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, and FANCM, orchestrating interstrand crosslink repair and genome stability maintenance through coordinated protein interactions. FANCA organizes tetratricopeptide repeats and leucine zippers that facilitate assembly of the multi-subunit complex at chromatin lesions while binding Hsp90 chaperone for stability and nuclear trafficking. Upon DNA damage from crosslinkers like mitomycin C, the FA complex activates FANCL E3 ligase to mono-ubiquitinate FANCD2-FANCI heterodimer, recruiting downstream effectors FANCJ/BRIP1, FANCD1/BRCA2, and FANCN/PALB2 for fork remodeling, translesion synthesis, and homologous recombination via strand invasion coordinated with the BRCA1/53BP1 axis. FANCA directly catalyzes single-strand annealing of resected double-strand breaks independent of canonical FA pathway components, annealing complementary overhangs through bidirectional strand exchange that competes with RAD52 to favor error-free repair outcomes during replication stress. Hsp90 association stabilizes FANCA conformation against proteasomal degradation, with 17-AAG inhibition disrupting nuclear localization and impairing FANCD2 activation that sensitizes cells to crosslinking agents. FANCA shuttles to pericentriolar material and kinetochores to regulate the spindle assembly checkpoint via BUB1-BUBR1 phosphorylation networks, preventing anaphase onset until bipolar attachment while suppressing chromosome fragmentation through ultrafine bridge resolution. FANCA safeguards hematopoietic stem cell quiescence and self-renewal by integrating replication stress responses with mitotic fidelity in bone marrow niches.

References
https://pubmed.ncbi.nlm.nih.gov/30525096/ https://pubmed.ncbi.nlm.nih.gov/30057198/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%